fT4 and fT3, positive TSH receptor antibodies and suppressed TSH. Similar scenarios of biotin interference can be imagined for extremely high steroid hormone concentrations with suppressed LH or FSH, which would be suggestive of tumors.
A broad range of laboratory tests beyond endocrine assays may be impacted similarly by biotin-induced interference, which can give rise to either very confusing results or very compelling factitious results. Extreme laboratory test values as well as clinically discordant ones may be easily recognized as interferences, but subtle or moderate biotin-induced changes in results would not be identifiable by the laboratory. Even a slight skewing of results can pose serious ramifications for tests in which misdiagnosis of serious infectious diseases such as HIV or hepatitis C virus or failure to recognize a tumor recurrence may occur. Emergency room patients may be at risk if biotin interferes with the assays for cardiac markers. Patients on thyroid medication may be titrated improperly owing to inaccurate but clinically congruous laboratory results. And the list goes on, and clinicians who recognize these problems will be looking to laboratorians for guidance.
While biotin interference in immunoassays has been known for years, it was a rare problem until biotin megadoses recently became commonplace. The ideal solution is to fix the biotin interference analytically, but this is a costly and a long-term proposition. Possible solutions may require removal of biotin in the assay design by pretreating samples with streptavidin or by adding biotin extraction steps. Such modifications will require extensive revalidation to demonstrate that performance is not affected. For now, laboratorians should become familiar with the availability of alternative assays that are free of biotin-streptavidin components to allow troubleshooting of discrepant results.
The practical and immediate solution to prevent or at least limit biotin interference will be to increase clinician and patient awareness of biotin's effects on tests. Physicians and other practitioners should inquire and advise patients to abstain from biotin intake for a few days before blood draw. This counsel is necessary although biotin has a very rapid elimination half-life of about 2 h; theoretically, most of it should clear from the body within 4 -5 h. However, pharmacokinetic studies of a patient ingesting megadoses (30 mg) of biotin revealed that its interfering effects on laboratory tests persisted for up to 24 h. For patients on megadoses of biotin, this finding means that it is prudent to stop taking biotin for at least 2 days before blood draws.
With biotin use being so pervasive, it is critical that laboratorians and clinicians are aware of biotin interference so that misdiagnosis and inappropriate treatment can be prevented. emy of Pediatrics, the National Lipid Association, and the American Heart Association have supported this recommendation, there has been substantial debate questioning this approach.
Fuel was added to the fire in this debate when in August of this year the US Preventive Services Task Force (USPSTF) issued a report on childhood dyslipidemia, concluding there is insufficient evidence either in support of or against universal lipid screening in children and adolescents (2 ) . A recent article published in Science entitled "Cholesterol screening for kids sparks debate (again)" addresses the impact of the USPSTF report, and presents views from both sides of this controversial topic.
In the article, Dr. Sarah de Ferranti, a representative of the American Academy of Pediatrics and cardiologist at Boston Children's Hospital, states that this organization continues to stand behind universal lipid screening in children and believes there are benefits to screening. Dr. Stephen Daniels, pediatrician-in-chief at Children's Hospital Colorado and Chair of the original 2011 National Heart, Lung, and Blood Institute expert panel report, expressed some regret at how the guidelines were initially presented, stating in retrospect there should have been more focus on identifying children with familial hypercholesterolemia, rather than universal screening.
Several opponents to the original 2011 guidelines expressed support for the 2016 USPSTF report. Dr. Peter Belamarich, pediatrician from Montefiore Medical Center in New York City, emphasized that universal screening addresses risk factors rather than a disease, and that there needs to be more proof that lipid-lowering therapies do not harm children. Dr. David Grossman, pediatrician at the Group Health Research Institute in Seattle, Washington, and vice chair of the USPSTF task force, additionally elaborated that the evidence of benefit of lipid-lowering therapies in children is lacking. Specifically, 13 clinical trials of statin use in children showed mixed results, and there are no long-term studies on the effects of these medications in children.
The article concludes that both sides agree more research is needed. One major challenge, however, relates to the logistics around designing a study that can effectively assess the impact of universal screening and lipidlowering therapies in childhood, when the cardiovascular disease sequelae present years or decades later. Given that an "ideal" study, if even feasible, would be decades away from completion leaves this debate settled in an uneasy place where clinicians continue to disagree as to whether the known sequelae of dyslipidemia combined with the known benefits of lipid-lowering therapies in adults can and should be applied to children. Unfortunately, if screening and treatment of hyperlipidemia in children is indeed effective in preventing or delaying cardiovascular morbidity and mortality, the hurdles to establishing sufficient longitudinal evidence to prove these hard outcomes may be too great to overcome, and children are ultimately the ones who will suffer from this lack of progress.
